Phosphodiesterase (PDE) Inhibitors Market Outlook:
Phosphodiesterase (PDE) Inhibitors Market size was valued at USD 4.8 billion in 2025 and is projected to reach USD 9.7 billion by the end of 2035, rising at a CAGR of 6.8% during the forecast period, i.e., 2026-2035. In 2026, the industry size of phosphodiesterase (PDE) inhibitors is estimated at USD 5.1 billion.
The global phosphodiesterase (PDE) inhibitors market is gaining immense exposure, fueled by its expanded consumer base. The increasing occurrence of cardiovascular diseases, erectile dysfunction, and pulmonary hypertension is driving business in this sector. In this regard WHO in July 2023 reported that cardiovascular diseases led to nearly 19.8 million deaths in a year, which is approximately 32% of all the deaths in the world. This rising disease incidence necessitates the requirement for PDE-5 inhibitors like sildenafil and tadalafil, appreciably accelerating market expansion.
Furthermore, the business in the sector is significantly influenced by the ongoing trade activities across all nations and firms that are enhancing their research efforts to bring innovations in this field. In this regard, it is reported that the U.S. and Europe are dominating the imports segment of finished products; similarly, China and India are leading with the API exports. Besides, CEIC data in 2021 states that the imports of medicines reached a substantial value of USD 92,622,441.159, reflecting the expanded necessity. Public-private collaborations under EMA are further accelerating clinical trials for novel PDE-4 inhibitors for COPD and psoriasis, thus denoting a positive market outlook.
